These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7186116)

  • 21. Hyperprolactinaemia and breast disease as evaluated by xeromammography.
    Calhaz-Jorge C; Cunha C; Nunes MC; Sobrinho LG
    Acta Endocrinol (Copenh); 1982 Jul; 100(3):347-50. PubMed ID: 7113603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The permanent effect of reproductive events on blood prolactin levels and its relation to breast cancer risk: a population study of postmenopausal women.
    Wang DY; de Stavola BL; Bulbrook RD; Allen DS; Kwa HG; Verstraeten AA; Moore JW; Fentiman IS; Hayward JL; Gravelle IH
    Eur J Cancer Clin Oncol; 1988 Jul; 24(7):1225-31. PubMed ID: 3416905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Plasma levels of prolactin in women with dysplasia and tumors of the breast (fibroadenoma and carcinoma of the breast)].
    Iturburu Belmonte IM; Basáñez Amuchastegui A; Jiménez Jiménez E; López de Tejada Cabeza I; Goicoechea García J; Méndez Martín J
    Rev Quir Esp; 1988; 15(1):17-21. PubMed ID: 3153353
    [No Abstract]   [Full Text] [Related]  

  • 24. Epidemiology of breast cancer.
    Marchant DJ
    Clin Obstet Gynecol; 1982 Jun; 25(2):387-92. PubMed ID: 7105514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactions between benign breast disease and other risk factors for breast cancer.
    Lubin JH; Brinton LA; Blot WJ; Burns PE; Lees AW; Fraumeni JF
    J Chronic Dis; 1983; 36(7):525-31. PubMed ID: 6874884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Assessment of selected hormonal parameters in patients with mastopathy in postmenopausal period].
    Mizia-Stec K; Zych F; Widala E
    Ginekol Pol; 1998 Feb; 69(2):56-61. PubMed ID: 9591381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultradian (12-hr) significant component in serum prolactin of healthy women and patients with fibrocystic mastopathy.
    D'Allesandro B; Esposito V; Lo Iudice G; Cagnoni M; Tarquini B
    Prog Clin Biol Res; 1987; 227B():281-4. PubMed ID: 3628338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Surgical evaluation of fibrocystic mastopathy. (Actuarial statistical study)].
    Ciuffini F; Consolandi G
    Acta Chir Ital; 1966; 22(5):499-526. PubMed ID: 5994397
    [No Abstract]   [Full Text] [Related]  

  • 29. [The steroid and peptide hormone content of the blood in women with different forms of fibrocystic mastopathy].
    Serov VN; Tumilovich LG; Rozhkova NI; Samoĭlova TE
    Akush Ginekol (Mosk); 1988 Mar; (3):54-6. PubMed ID: 3400830
    [No Abstract]   [Full Text] [Related]  

  • 30. Serum oestradiol-17 beta and prolactin concentrations during the luteal phase in women with benign breast disease.
    Walsh PV; McDicken IW; Bulbrook RD; Moore JW; Taylor WH; George WD
    Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1345-51. PubMed ID: 6542005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum prolactin levels in patients with fibrocystic breast disease.
    Peters F; Schuth W; Scheurich B; Breckwoldt M
    Obstet Gynecol; 1984 Sep; 64(3):381-5. PubMed ID: 6431348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The relationship between benign breast proliferation (fibrocystic mastopathy) and the appearance of breast carcinoma].
    Alexa O; Stolnicu S; Horváth E; Jung J
    Rev Med Chir Soc Med Nat Iasi; 2000; 104(4):101-9. PubMed ID: 12089936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [It is possible to prescribe a hormonal replacement therapy for a woman with proliferative mastopathy with atypia].
    Espié M; Cuvier C; Perret F; Cottu PH
    Gynecol Obstet Fertil; 2002 Apr; 30(4):331-5. PubMed ID: 12043510
    [No Abstract]   [Full Text] [Related]  

  • 34. Dietary and other risk factors in women having fibrocystic breast conditions with and without concurrent breast cancer: a nested case-control study in Shanghai, China.
    Li W; Ray RM; Lampe JW; Lin MG; Gao DL; Wu C; Nelson ZC; Fitzgibbons ED; Horner N; Hu YW; Shannon J; Satia JA; Patterson RE; Stalsberg H; Thomas DB
    Int J Cancer; 2005 Jul; 115(6):981-93. PubMed ID: 15723298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [It is not advisable to prescribe hormonal replacement therapy to a woman with proliferative mastopathy with atypia].
    Plu-Bureau G; Thalabard JC
    Gynecol Obstet Fertil; 2002 Apr; 30(4):335-9. PubMed ID: 12043511
    [No Abstract]   [Full Text] [Related]  

  • 36. [Management of mastopathy].
    Hoekman K; Bruning PF; van Dongen JA
    Ned Tijdschr Geneeskd; 1982 Nov; 126(46):2105-8. PubMed ID: 7177218
    [No Abstract]   [Full Text] [Related]  

  • 37. Chronic cystic masthopathya: twenty-five years experience.
    Papolczay A; Vörös A; Bihari I
    Acta Chir Acad Sci Hung; 1978; 19(4):349-56. PubMed ID: 757916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral contraceptive use and the risk of breast cancer in women with a "prior" history of benign breast disease.
    Stadel BV; Schlesselman JJ
    Am J Epidemiol; 1986 Mar; 123(3):373-82. PubMed ID: 3946384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Dynamics of gonadotropins and prolactin in dysplasias and cancer of the breast].
    Korolev VI; Skliar SIu; Ponomarev IN
    Vrach Delo; 1988 Jan; (1):59-61. PubMed ID: 3363942
    [No Abstract]   [Full Text] [Related]  

  • 40. Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer.
    Dupont WD; Page DL
    Am J Epidemiol; 1987 May; 125(5):769-79. PubMed ID: 3565352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.